Meda Sandra Orasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Meda Sandra Orasan has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Andrei Coneac
Department of Histology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
3 shared publications - Ștefan Cristian Vesa
Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, Iuliu Haţieganu University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania
3 shared publications - Alessandra-Madalina Matei-Man
Dermatology Department, Faculty of Medicine, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania
2 shared publications - Alexandra Dana Pușcaș
Independent Researcher, 1021 Budapest, Hungary
2 shared publications - Ana Calina Man
Life Sciences, Biotechnology Department, Harvard Extension School, Cambridge, MA 02138, USA
2 shared publications - Andreea Cătană
Department of Medical Genetics, “Iuliu Hațieganu” University of Medicine and Pharmacy, Pasteur Street 6, 400349 Cluj-Napoca, Romania
2 shared publications
Latest Publications
- Open Access
IL12B rs3213094 as a Predictor of Early Response to Biologic Therapy in Psoriasis: A Real-World Study in a Romanian Cohort
Background and Objectives: Psoriasis is a chronic immune-mediated inflammatory disease characterized by heterogeneous clinical presentation and variable response to biologic therapy. Genetic variation within the IL-23/Th17 inflammatory pathway may influence treatment outcomes. This study evaluated the association between IL12B rs3213094 and IL23R rs11209026 single-nucleotide polymorphisms (SNPs) and response to biologic therapy in patients with moderate-to-severe psoriasis. Materials and Methods: We conducted a multicenter observational study including 92 Romanian patients with moderate-to-severe psoriasis vulgaris receiving their first biologic therapy (anti-TNF, anti-IL-17, or anti-IL-23 monoclonal antibodies). Clinical response was assessed using the Psoriasis Area and Severity Index (PASI) at baseline and weeks 12, 24, 36, and 48. Early response was defined as achieving PASI75 at week 12. Patient-reported disease impact was assessed using the Dermatology Life Quality Index (DLQI) at the same time points. Genotyping of IL12B rs3213094 and IL23R rs11209026 was performed using TaqMan assays. Longitudinal PASI dynamics were analyzed using repeated-measures ANOVA, while multivariable logistic regression was used to identify independent predictors of PASI75 at week 12. Results: A significant reduction in PASI scores over time was observed (p < 0.001). The IL12B rs3213094 genotype was associated with differences in early response kinetics, with T-allele carriers showing significantly greater PASI improvement at week 12 compared with CC homozygotes (90.0% vs. 65.7%, p = 0.003). This effect was limited to early treatment and attenuated at later time points. In multivariable analysis, the IL12B rs3213094 CT + TT genotype was independently associated with PASI75 achievement at week 12 (OR = 4.285, 95% CI 1.500–12.239, p = 0.007). Treatment with anti-IL-17 agents was also an independent predictor of early response (OR = 3.946, 95% CI 1.416–10.998, p = 0.009). No significant association was observed between IL23R rs11209026 and treatment response. DLQI scores improved significantly over time (p < 0.001), without genotype-dependent differences. Conclusions: IL12B rs3213094 SNP is significantly associated with early biologic treatment response in psoriasis, supporting its potential role as a pharmacogenetic biomarker of treatment responsiveness. These findings may inform the integration of genetic markers into personalized therapeutic strategies, particularly in underrepresented populations such as those from Eastern Europe. Further studies in larger cohorts are warranted to validate these results.
Open AccessIL12B rs3213094 as a Predictor of Early Response to Biologic Therapy in Psoriasis: A Real-World Study in a Romanian Cohort
Background and Objectives: Psoriasis is a chronic immune-mediated inflammatory disease characterized by heterogeneous clinical presentation and variable response to biologic therapy. Genetic variation within the IL-23/Th17 inflammatory pathway may influence treatment outcomes. This study evaluated the association between IL12B rs3213094 and IL23R rs11209026 single-nucleotide polymorphisms (SNPs) and response to biologic therapy in patients with moderate-to-severe psoriasis. Materials and Methods: We conducted a multicenter observational study including 92 Romanian patients with moderate-to-severe psoriasis vulgaris receiving their first biologic therapy (anti-TNF, anti-IL-17, or anti-IL-23 monoclonal antibodies). Clinical response was assessed using the Psoriasis Area and Severity Index (PASI) at baseline and weeks 12, 24, 36, and 48. Early response was defined as achieving PASI75 at week 12. Patient-reported disease impact was assessed using the Dermatology Life Quality Index (DLQI) at the same time points. Genotyping of IL12B rs3213094 and IL23R rs11209026 was performed using TaqMan assays. Longitudinal PASI dynamics were analyzed using repeated-measures ANOVA, while multivariable logistic regression was used to identify independent predictors of PASI75 at week 12. Results: A significant reduction in PASI scores over time was observed (p < 0.001). The IL12B rs3213094 genotype was associated with differences in early response kinetics, with T-allele carriers showing significantly greater PASI improvement at week 12 compared with CC homozygotes (90.0% vs. 65.7%, p = 0.003). This effect was limited to early treatment and attenuated at later time points. In multivariable analysis, the IL12B rs3213094 CT + TT genotype was independently associated with PASI75 achievement at week 12 (OR = 4.285, 95% CI 1.500–12.239, p = 0.007). Treatment with anti-IL-17 agents was also an independent predictor of early response (OR = 3.946, 95% CI 1.416–10.998, p = 0.009). No significant association was observed between IL23R rs11209026 and treatment response. DLQI scores improved significantly over time (p < 0.001), without genotype-dependent differences. Conclusions: IL12B rs3213094 SNP is significantly associated with early biologic treatment response in psoriasis, supporting its potential role as a pharmacogenetic biomarker of treatment responsiveness. These findings may inform the integration of genetic markers into personalized therapeutic strategies, particularly in underrepresented populations such as those from Eastern Europe. Further studies in larger cohorts are warranted to validate these results.
- Open Access
Genetic Association Study of IL23R and IL12B Polymorphisms with Psoriasis in a Romanian Population
Background: Psoriasis is a chronic immune-mediated inflammatory disease with a strong genetic basis, driven in part by the dysregulation of the IL-23/Th17 signaling axis. Variants in the IL23R and IL12B genes have been associated with psoriasis susceptibility; however, data from Eastern European populations remains scarce. Objective: We aimed to evaluate the link between IL23R rs11209026 and IL12B rs3213094 polymorphisms and psoriasis susceptibility in a multi-center, Romanian cohort. Methods: We performed a multi-center case–control study including adult patients with clinically and histopathologically confirmed moderate-to-severe psoriasis undergoing biological therapy and controls without autoimmune or chronic inflammatory diseases. Genotyping was performed using TaqMan SNP assays. Associations were analyzed under a dominant genetic model. Results: A significant association was observed between IL23R rs11209026 polymorphism and psoriasis susceptibility. Carriers of the A allele (AA+GA) showed reduced odds of psoriasis compared with the GG homozygotes, emphasizing the protective effect of this specific variant. No significant association was identified for IL12B rs3213094 polymorphism. Conclusions: Our findings support the protective association of IL23R rs11209026 A allele with psoriasis in a Romanian Eastern European population and emphasize the importance of the IL-23 pathway in disease pathogenesis. Alcohol consumption was independently associated with increased risk of psoriasis. Further studies are justified to explore potential pharmacogenetic implications.
Open AccessGenetic Association Study of IL23R and IL12B Polymorphisms with Psoriasis in a Romanian Population
Background: Psoriasis is a chronic immune-mediated inflammatory disease with a strong genetic basis, driven in part by the dysregulation of the IL-23/Th17 signaling axis. Variants in the IL23R and IL12B genes have been associated with psoriasis susceptibility; however, data from Eastern European populations remains scarce. Objective: We aimed to evaluate the link between IL23R rs11209026 and IL12B rs3213094 polymorphisms and psoriasis susceptibility in a multi-center, Romanian cohort. Methods: We performed a multi-center case–control study including adult patients with clinically and histopathologically confirmed moderate-to-severe psoriasis undergoing biological therapy and controls without autoimmune or chronic inflammatory diseases. Genotyping was performed using TaqMan SNP assays. Associations were analyzed under a dominant genetic model. Results: A significant association was observed between IL23R rs11209026 polymorphism and psoriasis susceptibility. Carriers of the A allele (AA+GA) showed reduced odds of psoriasis compared with the GG homozygotes, emphasizing the protective effect of this specific variant. No significant association was identified for IL12B rs3213094 polymorphism. Conclusions: Our findings support the protective association of IL23R rs11209026 A allele with psoriasis in a Romanian Eastern European population and emphasize the importance of the IL-23 pathway in disease pathogenesis. Alcohol consumption was independently associated with increased risk of psoriasis. Further studies are justified to explore potential pharmacogenetic implications.
- Open Access
- 19 July 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (7) , 7719-7729
Inflammatory Cytokines and Clinical Outcome Following Biological Therapy in Adult Bio-Naïve Psoriasis Patients
Inflammatory cytokines may hold the key to the clinical evolution of psoriasis. The aims of this study are to find a correlation between levels of inflammatory cytokines such as TNF-α, IL-23, IL-17A, and IL-17F and disease duration and severity scores in psoriasis; to test if the decrease in any of the aforementioned cytokines is correlated with an amelioration in disease severity scores; and to analyze if any of the four biologic agents used are linked with a greater decrease in overall cytokine levels. We enrolled 23 adult patients under treatment with ixekizumab, secukinumab, guselkumab, or adalimumab and measured psoriasis disease severity scores PASI (Psoriasis Area Severity Index) and DLQI (Dermatology Life Quality Index), as well as the levels of the aforementioned cytokines at the start of therapy and after 3 months of continuous treatment. Inclusion criteria were the presence of psoriasis, age above 18 years and the need to initiate biological therapy (lack of response to standard treatment). Biological therapies resulted in an amelioration of PASI and DLQI scores, as well as levels of TNF-α, IL-23 and IL-17F. Disease duration and PASI and DLQI scores did not correlate with cytokine levels except DLQI and IL-23 score, in a paradoxically inversely proportional manner. IL-23, in particular, could be a useful biomarker for checking treatment response in psoriasis.
- 19 July 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (7) , 7719-7729
Open AccessInflammatory Cytokines and Clinical Outcome Following Biological Therapy in Adult Bio-Naïve Psoriasis Patients
Inflammatory cytokines may hold the key to the clinical evolution of psoriasis. The aims of this study are to find a correlation between levels of inflammatory cytokines such as TNF-α, IL-23, IL-17A, and IL-17F and disease duration and severity scores in psoriasis; to test if the decrease in any of the aforementioned cytokines is correlated with an amelioration in disease severity scores; and to analyze if any of the four biologic agents used are linked with a greater decrease in overall cytokine levels. We enrolled 23 adult patients under treatment with ixekizumab, secukinumab, guselkumab, or adalimumab and measured psoriasis disease severity scores PASI (Psoriasis Area Severity Index) and DLQI (Dermatology Life Quality Index), as well as the levels of the aforementioned cytokines at the start of therapy and after 3 months of continuous treatment. Inclusion criteria were the presence of psoriasis, age above 18 years and the need to initiate biological therapy (lack of response to standard treatment). Biological therapies resulted in an amelioration of PASI and DLQI scores, as well as levels of TNF-α, IL-23 and IL-17F. Disease duration and PASI and DLQI scores did not correlate with cytokine levels except DLQI and IL-23 score, in a paradoxically inversely proportional manner. IL-23, in particular, could be a useful biomarker for checking treatment response in psoriasis.
- Open Access
- 17 July 2019
- Published by IntechOpen
Evaluation of Psoriasis Patients
Psoriasis represents a chronic inflammatory skin disease with multisystemic involvement. The development of this autoimmune disorder depends on a complex interplay of genetic and environmental factors. Besides presenting the conditions associated with psoriasis, the chapter outlines the role of hormones (sex hormones, prolactin, and thyroid hormones) in psoriasis pathogenesis and evolution. The chapter indicates the clinical approaches recommended in practice: a detailed medical history collection (including prior exposure to treatments and evaluation of co-medication), a thorough physical examination (with the completion of specific severity and QoL scales), laboratory investigations and screening for malignancies (including lymphoma and skin cancer) or infection (Tuberculosis, Crohn’s disease). European Guidelines encourage the dermatologist to check for hypersensitivity, metabolic, gastro-intestinal and renal disorders, check for the need of vaccines and contraception. We discuss pre-treatment, during-treatment and post-treatment evaluation options and underline the necessity of clear evaluation steps in the assessment of psoriasis patients.
- 17 July 2019
- Published by IntechOpen
Open AccessEvaluation of Psoriasis Patients
Psoriasis represents a chronic inflammatory skin disease with multisystemic involvement. The development of this autoimmune disorder depends on a complex interplay of genetic and environmental factors. Besides presenting the conditions associated with psoriasis, the chapter outlines the role of hormones (sex hormones, prolactin, and thyroid hormones) in psoriasis pathogenesis and evolution. The chapter indicates the clinical approaches recommended in practice: a detailed medical history collection (including prior exposure to treatments and evaluation of co-medication), a thorough physical examination (with the completion of specific severity and QoL scales), laboratory investigations and screening for malignancies (including lymphoma and skin cancer) or infection (Tuberculosis, Crohn’s disease). European Guidelines encourage the dermatologist to check for hypersensitivity, metabolic, gastro-intestinal and renal disorders, check for the need of vaccines and contraception. We discuss pre-treatment, during-treatment and post-treatment evaluation options and underline the necessity of clear evaluation steps in the assessment of psoriasis patients.
- Open Access
- 31 October 2018
- Published by IntechOpen
Evaluation of Patients with Alopecia
This chapter outlines the clinical approaches for alopecic patients that are reliable in practice. We discuss three different categories of hair evaluation options: invasive methods (biopsy), semi-invasive methods (trichogram) and noninvasive methods. Besides describing the current status of diagnosis and quantification of alopecia, the chapter provides an objective assessment of these investigation tools: detailed medical history collection by structured interview and questionnaires, clinical examination of the scalp and other hair-bearing areas, laboratory investigations, assessment of hair loss distribution (patterned/diffuse/focal), dermoscopic evaluation, assessment of alopecia severity (by pull test, hair part width, counting hair test), common scales for hair loss staging, photography of alopecic areas, biopsy, trichogram, unit area trichogram, tug test, hair mount and microscopic evaluation, electron microscopy, hair card test, hair weight determination, hair densitometry, mechanical test of hair quality and computed hair analysis. Unfortunately, the disadvantages of most of these methods generate a lack of use in clinical practice, leading to few reliable evaluation methods for patients suffering from alopecia. We underline the necessity of easy, refined and precise evaluation tools for the assessment of alopecia patients.
- 31 October 2018
- Published by IntechOpen
Open AccessEvaluation of Patients with Alopecia
This chapter outlines the clinical approaches for alopecic patients that are reliable in practice. We discuss three different categories of hair evaluation options: invasive methods (biopsy), semi-invasive methods (trichogram) and noninvasive methods. Besides describing the current status of diagnosis and quantification of alopecia, the chapter provides an objective assessment of these investigation tools: detailed medical history collection by structured interview and questionnaires, clinical examination of the scalp and other hair-bearing areas, laboratory investigations, assessment of hair loss distribution (patterned/diffuse/focal), dermoscopic evaluation, assessment of alopecia severity (by pull test, hair part width, counting hair test), common scales for hair loss staging, photography of alopecic areas, biopsy, trichogram, unit area trichogram, tug test, hair mount and microscopic evaluation, electron microscopy, hair card test, hair weight determination, hair densitometry, mechanical test of hair quality and computed hair analysis. Unfortunately, the disadvantages of most of these methods generate a lack of use in clinical practice, leading to few reliable evaluation methods for patients suffering from alopecia. We underline the necessity of easy, refined and precise evaluation tools for the assessment of alopecia patients.
- Open Access
- 23 May 2018
- Published by IntechOpen
Evaluation of Animal Models Suitable for Hair Research and Regeneration
Hair loss and regeneration are the subjects of tremendous amount of research for multiple reasons: the well-known importance of hair in individual beauty, the fact that alopecia is a frequent dermatological disease, and that there are limited treatment options. The present work focuses on the evaluation of animal models used for hair research and regeneration. Besides mentioning the option of in vitro studies, the chapter analyzes the need of an animal model of alopecia, common used study designs, hair regrowth evaluation methods, and the limitations of the animal models in hair regrowth research. This chapter also discusses the structure of hair, its chemical composition, the properties and functions of hair, consequences of hair loss, the biology of hair loss, and regeneration and existing treatment options for alopecia. By using proper and well thought-out animal models, we aim to refine our knowledge on human hair diseases and hair regrowth. Hair research provides insights into the physiopathological pathways, genetic and cell biochemical mechanisms, and remains a field intensively explored and still inexhaustible.
- 23 May 2018
- Published by IntechOpen
Open AccessEvaluation of Animal Models Suitable for Hair Research and Regeneration
Hair loss and regeneration are the subjects of tremendous amount of research for multiple reasons: the well-known importance of hair in individual beauty, the fact that alopecia is a frequent dermatological disease, and that there are limited treatment options. The present work focuses on the evaluation of animal models used for hair research and regeneration. Besides mentioning the option of in vitro studies, the chapter analyzes the need of an animal model of alopecia, common used study designs, hair regrowth evaluation methods, and the limitations of the animal models in hair regrowth research. This chapter also discusses the structure of hair, its chemical composition, the properties and functions of hair, consequences of hair loss, the biology of hair loss, and regeneration and existing treatment options for alopecia. By using proper and well thought-out animal models, we aim to refine our knowledge on human hair diseases and hair regrowth. Hair research provides insights into the physiopathological pathways, genetic and cell biochemical mechanisms, and remains a field intensively explored and still inexhaustible.